Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes

European Journal of Cancer

Volumn 36, Issue 7, 2000, Pages 845-851

  Cameron, D A ^a,b   Keen, J C ^a   Dixon, J M ^a   Bellamy, C ^b   Hanby, A ^c   Anderson, T J ^a,b,c   Miller, W R ^a,b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Breast cancer; Mitosis; Response; Tamoxifen

Indexed keywords

PROTEIN BCL 2; TAMOXIFEN;

AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS INDEX; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MITOSIS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAMOXIFEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034053157     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00013-7     Document Type: Article

References (31)

1. Tamoxifen for early breast cancer. an overview of the randomised trials Lancet. 351:1998;1451-1467.
2. Osborne C.K., Yochmowitz M.G., Knight W.A., McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 46:1980;2884-2888.
3. Williams M.R., Todd J.H., Ellis I.O.et al. Oestrogen receptors in primary and advanced breast cancer. an eight year review of 704 cases Br. J. Cancer. 55:1987;67-73.
4. Brooks S.C., Saunders D.E., Singhakowinta A., Vaitkevicius V.K. Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer. 46:1980;2775-2778.
5. Keen J.C., Dixon J.M., Miller E.P.et al. The expression of KiS-1 and bcl-2 and the response to primary tamoxifen therapy in elderly patients with primary breast cancer. Breast Cancer Res. Treat. 44:1997;123-133.
6. Hockenbery D.M., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
7. Cohen J.J. Apoptosis. Immunol. Today. 14:1993;126-130.
8. Jannink I., van Diest P.J., Baak J.P.A. Comparison of the prognostic value of mitotic frequency and mitotic activity index in breast cancer. Breast. 5:1996;31-36.
9. Brugal G., Dye R., Krief B., Chassery J.-M., Tanke H., Tucker J.H. HOME. Highly Optimized Microscope Environment Cytometry. 13:1992;109-116.
10. Bland J.M., Altman D.G. Measurement error. Br. Med. J. 313:1996;744.
11. Bland J.M., Altman D.G. Measurement error and correlation coefficients. Br. Med. J. 313:1996;41-42.
12. Danova M., Pellicciari C., Zibera C.et al. Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. Ann. New York Acad. Sci. 698:1993;174-181.
13. Sutherland R.L., Hall R.E., Tayor I.W. Cell proliferation kinetics of MCF7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 43:1983;3998-4006.
14. Watts C.K.W., Sweeney K.J.E., Warlters A., Musgrove E.A., Sutherland R.L. Antiestrogen regulation of cell cycle progression and cyclin D1 expression in MCF-7 human breast cancer cells. Breast Cancer Res. Treat. 31:1994;95-105.
15. Bardon S., Vignon F., Montcourrier P., Rochefort H. Steroid-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res. 47:1987;1441-1448.
16. Chen H., Tritton T.R., Kenny N., Absher M., Chiu J.F. Tamoxifen induces TGF β1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J. Cell Biochem. 61:1996;9-17.
17. Chan WK, Poulsom R, Lu QL, et al. bcl2 expression in invasive mammary carcinoma: correlation with apoptosis, hormone receptors and p53 expression. J Pathol 1993, 169(Suppl.), 153 (abstr).
18. Lipponen P., Pietilainen T., Kosma V.M., Aaltomaa S., Eskelinen M., Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favorable prognosis. J. Pathol. 177:1995;49-55.
19. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Cancer. 68:1991;1309-1317.
20. Johnston S.R.D., MacLennan K.A., Sacks N.P.M., Salter J., Smith I.E., Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur. J. Cancer. 30A:1994;1663-1669.
21. Clarke R.B., Laidlaw I.J., Jones L.J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br. J. Cancer. 67:1993;606-611.
22. Teixeira C., Reed J.C., Pratt M.A.C. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving proto-oncogene expression in human breast cancer cells. Cancer Res. 55:1995;3902-3907.
23. Wang T.T.Y., Phang J.M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55:1995;2487-2489.
24. Lipponen P., Aaltomaa S., Kosma V.M., Syrjanen K. Apoptosis in breast-cancer as related to histopathological characteristics and prognosis. Eur. J. Cancer. 30A:1994;2068-2073.
25. Lipponen P.K., Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J. Pathol. 173:1994;333-339.
26. Czader M., Mazur J., Pettersson M.et al. Prognostic significance of proliferative and apoptotic fractions in low grade follicle center cell-derived Non-Hodgkin's lymphomas. Cancer. 77:1996;1180-1188.
27. Arends M.J., McGregor A.H., Wyllie A.H. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras and HPV oncogenes. Am. J. Pathol. 144:1994;1045-1057.
28. Cameron D.A., Ritchie A.A., Langdon S., Anderson T.J., Miller W.R. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res. Treat. 45:1997;99-107.
29. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:1997;614-620.
30. Lundberg A.S., Weinberg R.A. Control of the cell cycle and apoptosis. Eur. J. Cancer. 35:1999;531-539.
31. Pepper C., Hoy M., Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer. 76:1997;935-938.